Epstein Secrets

startup. Cambridge-based Editas Medicine is announcing a $120 million Series B round led by Bill Gates's chief advisor for science and technology, Boris Nikolic. The list of financiers teaming with Nikolic reads like a rolodex of so-called crossover investors, who invest in both public and private entities,

ncing a $120 million Series B round led by Bill Gates's chief advisor for science and technology, Boris Nikolic. The list of financiers teaming with Nikolic reads like a rolodex of so-called crossover investors, who invest in both public and private entities, and corporate venture arms. Among them: Deer

ates's chief advisor for science and technology, Boris Nikolic. The list of financiers teaming with Niko

s, and corporate venture arms. Among them: Deerfield Management, Viking Global Investors, Fidelity Management & Research, T. Rowe Price Associates, Google Ventures, Jennison Associates, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments, and Alexandria Venture Investments. E

1990 and 1992 and subsequently joined the World Bank where he was involved in the development of the financial sector in Russia. Boris Nlkolk Dr. Boris Nikolic is a Chief Advisor for Science and Technology to Bill Gates at Bill Gates Catalyst 3 (bgc3), Bill Gates Ventures (BGV) and at the Bill & Melinda Gat

Science and Technology to Bill Gates at Bill Gates Catalyst 3 (bgc3), Bill Gates Ventures (BGV) and at the Bill & Melinda Gates Foundation (BMGF). Boris has led investment activities at these Gates-affiliated organizations on both the for-profit and non-for-profit aspects of Bill Gates' activities.

ceived his MD from Zagreb Medical School and his clinical training from the University's Medical Center, University of Zagreb, Croatia. In 1994, Dr. Nikolic joined the Harvard Graduate Program in Immunology. Subsequently, Boris continued to serve in roles of increasing authority including postdoctoral f

ted revenue of S29m. In December 2012, the Principals invested Slim at a valuation of 5204m. Other investors in the round included Kleiner Perkins, Google Ventures, Roche and Labcorp. In September 2013, J.P. Morgan and Goldman Sachs led the IPO of Foundation Medicine. As of 240, January 2014, Foundation Medici

From: Boris Nikolic < Sent: Thursday, May 8, 2014 11:23 AM To: Jeffrey Epstein ([email protected]) Subject: FW: Small part of A BIG DEAL This is one I missed &=82

ent =n. How long are you in NY=? B From: Eli Casdin Sent: Thursday, May 8, 2014 7:14 AM To: Boris Nikolic Subject: Small part of A BIG DEAL Hi Boris, Apologies for my barrage of emails recently but I wa=ted to call out our latest private investment into Flatiron Health. We wer= extremely excited

From: Boris Nikolic < Sent: Thursday, May 8, 2014 11:23 AM To: Je

gy treatments and has the potentia= to bend the curve on costs while at the same time improving patient outcomes. As Bill Maris, managing=partner of Google Ventures commented in the WSJ reporting "We don :=17;t generally make investments of $100-plus million, when we do make an i=vestment of this size, it means